Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly

Manas K Akmatov, Peggy Riese, Stephanie Trittel, Marcus May, Jana Prokein, Thomas Illig, Christoph Schindler, Carlos A Guzmán, Frank Pessler, Manas K Akmatov, Peggy Riese, Stephanie Trittel, Marcus May, Jana Prokein, Thomas Illig, Christoph Schindler, Carlos A Guzmán, Frank Pessler

Abstract

Background: The immune response to seasonal influenza vaccines decreases with advancing age. Therefore, an adjuvanted inactivated trivalent influenza vaccine (Fluad®) exists for elderly individuals. Fluad® is more immunogenic and efficacious than conventional influenza vaccines. However, the immune response varies and may still result in high frequencies of poor responders. Therefore, we aimed to a) examine the prevalence of a weak response to Fluad® and b) identify potential risk factors.

Methods: A prospective population-based study among individuals 65-80 years old was conducted in 2015/2016 in Hannover, Germany (n = 200). Hemagglutination-inhibition titers 21 days after vaccination with Fluad® served as indicator of vaccine responsiveness.

Results: The percentage of vaccinees with an inadequate vaccine response varied depending on the influenza strain: it was lowest for H3N2 (13.5%; 95% CI, 9.4-18.9%), intermediate for B strain (37.0%; 30.6-43.9%), and highest for H1N1 (49.0%; 42.2-55.9%). The risk of a weak response to the influenza A H1N1 strain was independently associated with self-reported diabetes (AOR, 4.64; 95% CI, 1.16-18.54), a history of herpes zoster (2.27; 1.01-5.10) and, to a much lesser extent, increasing age (change per year, 1.08; 0.99-1.16). In addition, herpes zoster was the only risk factor for a weak response to the H3N2 antigen (AOR, 3.12; 1.18-8.23). We found no significant association between sex, Body Mass Index, cancer, hypertension, heart attack and CMV seropositivity and a weak response to these two influenza A antigens. Despite its occurence in over one third of vaccinees, none of the variables examined proved to be risk factors for a weak response to the B antigen.

Conclusions: A considerable proportion of elderly individuals displayed a weak vaccine response to this adjuvanted seasonal influenza vaccine and further efforts are thus needed to improve immune responses to influenza vaccination among the elderly. Diabetes and herpes zoster were identified as potentially modifiable risk factors for a poor vaccine response against influenza A antigens, but the results also reveal the need for broader investigations to identify risk factors for inadequate responses to influenza B antigens.

Trial registration: No. NCT02362919 (ClinicalTrials.gov, date of registration: 09.02.2015).

Keywords: Diabetes; Elderly; Fluad®; Herpes zoster; Influenza vaccination.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CMV-specific IgG by participants’ age*. * Estimated by fractional polynomials; the best powers for age among 44 models were − 2, −2
Fig. 2
Fig. 2
Venn diagram showing common and distinct humoral responses to the three antigens contained in the vaccine (i.e. A H1N1, A H3N2 and B). Percent values do not sum up to 100%; 71 (35.5%) participants had an adequate response to all three antigens

References

    1. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159–1169. doi: 10.1016/j.vaccine.2005.08.105.
    1. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De MM. Immunosenescence and infectious diseases. Microbes Infect. 2001;3:851–857. doi: 10.1016/S1286-4579(01)01443-5.
    1. Reber A, Kim J, Biber R, Talbot H, Coleman L, Chirkova T, et al. Preexisting immunity, more than aging, influences influenza vaccine responses. Open Forum Infect Dis. 2015;2:ofv052. doi: 10.1093/ofid/ofv052.
    1. Andrews SF, Kaur K, Pauli NT, Huang M, Huang Y, Wilson PC. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J Virol. 2015;89:3308–3317. doi: 10.1128/JVI.02871-14.
    1. Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala M, Mysliwski A. Immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp Gerontol. 2004;39:1447–1458. doi: 10.1016/j.exger.2004.08.005.
    1. Sagawa M, Kojimahara N, Otsuka N, Kimura M, Yamaguchi N. Immune response to influenza vaccine in the elderly: association with nutritional and physical status. Geriatr Gerontol Int. 2011;11:63–68. doi: 10.1111/j.1447-0594.2010.00641.x.
    1. Pawelec G, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fulop T, et al. Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing. 2010;7:13. doi: 10.1186/1742-4933-7-13.
    1. Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, Bunce M, et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis. 2002;185:114–117. doi: 10.1086/338014.
    1. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008;26(Suppl 4):D35–D40. doi: 10.1016/j.vaccine.2008.07.065.
    1. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172–180. doi: 10.1086/599790.
    1. Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine. 2017;35:2775–2780. doi: 10.1016/j.vaccine.2017.03.092.
    1. Arnou R, Icardi G, De DM, Ambrozaitis A, Kazek MP, Weber F, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312. doi: 10.1016/j.vaccine.2009.10.033.
    1. Tsai TF. Fluad(R)-MF59(R)-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother. 2013;45:159–174. doi: 10.3947/ic.2013.45.2.159.
    1. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. Clin Exp Vaccine Res. 2017;6:38–44. doi: 10.7774/cevr.2017.6.1.38.
    1. Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35:513–520. doi: 10.1016/j.vaccine.2016.12.011.
    1. Akmatov MK, Riese P, May M, Jentsch L, Ahmed M, Werner D, et al. Establishment of a cohort for deep phenotyping the host response to influenza vaccination among elderly individuals recruited from the general population. Hum Vaccin Immunother. 2017;10:10.
    1. Akmatov MK, Jentsch L, Riese P, May M, Ahmed MW, Werner D, et al. Motivations for (non) participation in population-based studies among the elderly - comparison of participants and nonparticipants of a prospective study on influenza. BMC Med Res Methodol. 2017;17:18. doi: 10.1186/s12874-017-0302-z.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2.
    1. Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statist Med. 1998;17:857–872. doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>;2-E.
    1. Destatis. German population by sex and age. . Accessed 1 Sept 2016.
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28:964–974. doi: 10.1093/ije/28.5.964.
    1. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19:1059–1079. doi: 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>;2-0.
    1. Trzonkowski P. Effect of anti-influenza vaccination on immune system in the elderly. In: Fulop T, Franceschi C, Hirokawa K, Pawelec G, editors. Handbook on immunosenescence. Basic understanding and clinical applications. Dordrecht: Springer; 2009. p. 1455–86.
    1. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines. 2012;11:985–994. doi: 10.1586/erv.12.61.
    1. Wittek M, Doerr HW, Allwinn R. Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 2010;105:334–338. doi: 10.1007/s00063-010-1061-3.
    1. Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. J Diabetes Res. 2017;2017:6494795. doi: 10.1155/2017/6494795.
    1. Sheridan PA, Paich HA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens M, et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine. 2015;33:3306–3313. doi: 10.1016/j.vaccine.2015.05.043.
    1. McElhaney JE, Garneau H, Camous X, Dupuis G, Pawelec G, Baehl S, et al. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3:e000140. doi: 10.1136/bmjdrc-2015-000140.
    1. Rokni H, Haroon N, McElnaney J. Immune response to influenza vaccination in older adults: interactions with type 2 diabetes. Sci Pages Diabetol. 2016;1:6–7.
    1. Tamayo T, Brinks R, Hoyer A, Kuss OS, Rathmann W. The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int. 2016;113:177–182.
    1. Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Inf Secur. 2015;70:178–186.
    1. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173. doi: 10.1186/1471-2334-11-173.
    1. Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, et al. An update on Inflamm-aging: mechanisms, prevention, and treatment. J Immunol Res. 2016;2016:8426874. doi: 10.1155/2016/8426874.
    1. Franceschi C, Bonafe M, Valensin S, Olivieri F, De LM, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254. doi: 10.1111/j.1749-6632.2000.tb06651.x.
    1. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435–446. doi: 10.1111/j.1365-2567.2007.02555.x.
    1. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144–156. doi: 10.1002/path.2104.
    1. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36:1072–1077. doi: 10.1038/ijo.2011.208.
    1. Gowda C, McKittrick N, Kim D, Kappes RA, Lo RV, III, Tebas P. Obesity is not associated with impaired immune response to influenza vaccination in HIV-infected persons. AIDS Res Treat. 2015;2015:653840.
    1. Sweet MA, McCullers JA, Lasala PR, Briggs FE, Smithmyer A, Khakoo RA. Comparison of immune response to the influenza vaccine in obese and nonobese healthcare workers. Infect Control Hosp Epidemiol. 2015;36:249–253. doi: 10.1017/ice.2014.59.
    1. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine. 2012;30:3937–3943. doi: 10.1016/j.vaccine.2012.03.071.
    1. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009;19:47–56. doi: 10.1002/rmv.598.
    1. Derhovanessian E, Theeten H, Hahnel K, Van DP, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013;31:685–690. doi: 10.1016/j.vaccine.2012.11.041.
    1. Trzonkowski P, Mysliwska J, Pawelec G, Mysliwski A. From bench to bedside and back: the SENIEUR protocol and the efficacy of influenza vaccination in the elderly. Biogerontology. 2009;10:83–94. doi: 10.1007/s10522-008-9155-5.
    1. den Elzen WP, Vossen AC, Cools HJ, Westendorp RG, Kroes AC, Gussekloo J. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine. 2011;29:4869–4874. doi: 10.1016/j.vaccine.2011.03.086.
    1. Haq K, Fulop T, Tedder G, Gentleman B, Garneau H, Meneilly GS, et al. Cytomegalovirus Seropositivity predicts a decline in the T cell but not the antibody response to influenza in vaccinated older adults independent of type 2 diabetes status. J Gerontol A Biol Sci Med Sci. 2017;72:1163–1170.
    1. Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med. 2015;7:281ra43. doi: 10.1126/scitranslmed.aaa2293.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel